88IV - Public company info - Keymed Biosciences Inc.

Input the stock code or the company name

Keymed Biosciences Inc., 02162.HK - Cash Flow	2021-12	2020-12	2019-12
Net Cash Flow from Operating Activities	-214,637	-119,361	-68,379
Net Cash Flow from Return on Investments & Servicing of Finance	5,964	4,711	1,117
Interest Received	5,964	4,711	1,117
Interest Paid	0	0	0
Dividend Received	0	0	0
Dividend Paid	0	0	0
Others	0	0	0
Taxes (Paid) / Refunded	0	0	0
Net Cash Flow from Investing Activities	-2,041,843	-117,778	-59,137
Additions to Fixed Assets	-171,786	-19,806	-62,264
Disposal of Fixed Assets	0	0	0
Increase in Investments	-203,523	-329,500	-257,000
Decrease in Investments	140,565	385,600	260,165
Net Cash Flow with Related Parties	-41,820	9,386	100,239
Others	-1,765,279	-163,458	-100,277
Net Cash Flow before Financing Activities	-2,250,516	-232,428	-126,399
Net Cash Flow from Financing Activities	3,638,376	7,397	505,066
New Loans	0	0	0
Loans Repayment	-9,684	-5,464	-5,673
Fixed Income/Debt Instruments	872,111	3,475	410,500
Repayment of Fixed Income/Debt Instruments	-58,154	0	0
Equity Financing	2,879,144	0	0
Net Cash Flow with Related Parties	-41,820	9,386	100,239
Others	-3,221	0	0
Increase(Decrease) in Cash & Cash Equivalents	1,387,860	-225,031	378,667
Cash & Cash Equivalents at Beginning of Year	199,409	432,608	48,799
Net Cash Flow due to Change in Exchange Rate/Others	-66,650	-8,168	5,142
Cash & Cash Equivalents at End of Year	1,520,619	199,409	432,608
Currency	Renminbi	Renminbi	Renminbi
Unit
Auditor's Opinion	1	0	0

Notes:1–Unqualified; 2–Unqualified ( not qualified in respect of fundamental uncertainly because of proper disclosure); 3–Qualified

Public company info - Keymed Biosciences Inc. , 02162.HK